Women are 48% of new cancer cases, 45% of CVD patients, and 80% of household healthcare decision-makers. Most systems are investing in oncology and cardiology capacity. Fewer are asking what determines which system wins the referral.
The pipeline already exists. Women account for nearly half of all new cancer cases and nearly half of all cardiovascular disease patients. The question is not whether the demand is there — it is which system wins it.
"Most systems treat mammography as a commodity imaging service. The ones that treat it as a patient acquisition and loyalty platform end up winning the referral."
Mammography is the highest-frequency recurring touchpoint in a health system — reaching healthy women on a schedule, every year, before symptoms arise. It is where the care relationship is established, not a downstream consequence of one opportunity.
A system that delivers a differentiated experience here doesn't compete for the referral. It already has the relationship when the referral is needed.
A 20-percentage-point difference in screening compliance — the gap between a managed-down imaging department and a purpose-built mammography platform — translates directly into oncology and cardiology revenue. Experience is the operating lever.
Screening compliance across most system-operated programs. Driven by scheduling friction, generic patient experience, and minimal recall infrastructure.
Est. $8.3M oncology revenue per 100K eligible women annually
Achieved when scheduling access, patient experience, and recall programs are purpose-built around the woman — not inherited from a general imaging workflow.
Est. $11.6M+ oncology revenue per 100K eligible women annually
Per 1,000 screens: ~5 cancers detected at ~$33K avg. oncology revenue per patient. Est. at 60% in-system capture. Source: ACR/BCSC; Merritt Hawkins/AMN Healthcare 2023; ACS Cancer Facts & Figures 2025.
Online, same-day, and evening access. Women don't skip mammograms because they don't want them — they skip because booking one is inconvenient. Friction is the largest compliance enemy.
Systematic recall programs with personalized outreach recover 15–20% of lapsed patients. Most health systems have no structured recall infrastructure at all. This is a direct compliance lever.
Women seen in a dedicated, women-focused setting return at materially higher rates than those processed through a general imaging department. The environment signals that the system sees them.
Rapid TAT and proactive abnormal-result navigation — not just mailing results — are the primary determinant of whether the oncology referral stays in-system or leaks to a competitor.
Best-in-class CDR. ACR benchmark average is 3–6/1,000. Higher detection means more women entering the oncology pipeline in-system.
Within ACR optimal range. Too low misses cancers; too high drives unnecessary anxiety and cost. Precision recall reflects radiologist quality.
Top-quartile positive predictive value on recommended biopsies. Higher PPV3 means fewer unnecessary procedures — better outcomes and lower system cost.
Top decile in healthcare, sustained network-wide. Clinical quality and patient experience are not trade-offs — they are the same operating model.
CDR, recall rate, and PPV3: Solis network data benchmarked against ACR/BCSC standards.
A CDR above 4/1,000 is not achieved by accident. It requires the right radiologist protocols, the right imaging technology, and enough volume to maintain clinical acuity. The same platform that drives consumer experience — dedicated environment, purpose-built workflows, continuous AI investment — is what produces best-in-class clinical outcomes.
Dedicated platform partnership · Top 50 MSA · Results measured through Year 5.
Up from ~50% health system average. Driven by scheduling infrastructure and recall programs deployed from day one.
More women screened, higher detection rate capture, and in-system navigation driving referral retention.
A service line previously treated as a cost center became the system's highest-value patient acquisition engine.
Maintained network-wide over five years. The patient experience infrastructure that drives compliance is the same infrastructure that drives NPS.
All outcomes from a single Top 50 MSA partnership, launched 2019, measured through Year 5.
Every input in the revenue model is knowable from your own data — screening volume, compliance rate, in-system capture, payor mix. Solis will build a market-specific analysis for your system, at no cost and with no commitment required.
Request Your Market AnalysisNo commitment required · Built using your data · Delivered within 2 weeks